Increased Expression of the p-STAT3/IL-17 Signaling pathway in patients with Dermatomyositis.

OBJECTIVE To explored the roles of phosphorylated signal transduction and activator of transcription 3 (p-STAT3) and IL (interleukin) -17 in patients with dermatomyositis (DM). METHODS A total of 20 DM patients and 12 healthy controls were enrolled. The Flow cytometry combined with counting was used to detect the numbers of Th17 cells. Western blotting and immunohistochemistry was used to examine the muscle levels of p-STAT3 and IL-17, and serum levels of IL-17 were measured by enzyme-linked immunosorbent assays. RESULTS Muscle p-STAT3 and IL-17 levels, the numbers of Th17 cells, and serum IL-17 levels were markedly increased in DM. p-STAT3 and IL-17 were co-expressed in the muscle of DM patients. The p-STAT3 levels correlated with the number of Th17 cells as well as muscle and serum IL-17 levels. The correlations of the p-STAT3 level with elevated levels of transaminases, myocardial enzymes, and the health assessment questionnaire score were significantly positive, while the correlation with manual muscle testing-8 was significantly negative. A receiver operating characteristic curve indicated good predictive value of p-STAT3 for the occurrence of DM. CONCLUSION The increased p-STAT3/IL-17 signaling pathway activation in DM patients may induce muscle inflammation and necrosis, and it may be a potential target for DM.

[1]  M. Gatto,et al.  Lymphocyte immunophenotyping in inflammatory myositis: a review , 2021, Current opinion in rheumatology.

[2]  Guifen Shen,et al.  Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy , 2021, International journal of rheumatic diseases.

[3]  W. El-Rifai,et al.  NF-kB-dependent activation of STAT3 by H. pylori is suppressed by TFF1 , 2021, Cancer Cell International.

[4]  A. Ogdie,et al.  Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study. , 2020, Rheumatology.

[5]  M. Khamaisi,et al.  Mortality in Patients with Polymyositis and Dermatomyositis in an Israeli Population. , 2020, The Israel Medical Association journal : IMAJ.

[6]  Y. Hathout,et al.  Serum protein biomarkers for juvenile dermatomyositis: a pilot study , 2020, BMC Rheumatology.

[7]  Wei Huang,et al.  Targeting STAT3 in Cancer Immunotherapy , 2020, Molecular cancer.

[8]  J. Lamb,et al.  239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018 , 2019, Neuromuscular Disorders.

[9]  Kai Zhu,et al.  Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? , 2019, European journal of medicinal chemistry.

[10]  Yuxuan Li,et al.  Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[11]  D. Isenberg,et al.  Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. , 2019, Rheumatology.

[12]  S. Gaffen,et al.  The IL-17 Family of Cytokines in Health and Disease. , 2019, Immunity.

[13]  Dongping Yuan,et al.  Yangyin Qingre Huoxue Method in Traditional Chinese Medicine Ameliorates Atherosclerosis in ApoE−/− Mice Suffering from High-Fat Diet and HSP65 Aggression , 2019, Evidence-based complementary and alternative medicine : eCAM.

[14]  A. Mammen,et al.  Classification and management of adult inflammatory myopathies , 2018, The Lancet Neurology.

[15]  C. Sotiriou,et al.  p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. , 2017, International journal of oncology.

[16]  W. Jiang,et al.  The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway , 2017, Oncotarget.

[17]  Ding Luo,et al.  IL-17 Activates the IL-6/STAT3 Signal Pathway in the Proliferation of Hepatitis B Virus-Related Hepatocellular Carcinoma , 2017, Cellular Physiology and Biochemistry.

[18]  T. Dai,et al.  Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis , 2017, Chinese medical journal.

[19]  Y. Parman,et al.  Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis. , 2017, In vivo.

[20]  M. Veldhoen Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.

[21]  A. Cavani,et al.  IL‐17 and IL‐22 in immunity: Driving protection and pathology , 2017, European journal of immunology.

[22]  C. Crowson,et al.  Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis , 2017, The Journal of Rheumatology.

[23]  M. Santis,et al.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review , 2017, Clinical Reviews in Allergy & Immunology.

[24]  Oakley,et al.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015 , 2016, Neuromuscular Disorders.

[25]  O. Harismendy,et al.  Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. , 2016, Cell reports.

[26]  N. Esa,et al.  Allicin Alleviates Dextran Sodium Sulfate- (DSS-) Induced Ulcerative Colitis in BALB/c Mice , 2015, Oxidative medicine and cellular longevity.

[27]  I. Lundberg,et al.  Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies , 2015, Scandinavian journal of rheumatology.

[28]  T. Macdonald,et al.  Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth , 2014, Oncogene.

[29]  F. Iannone,et al.  Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. , 2014, Reumatismo.

[30]  Andrew McKenzie,et al.  Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation , 2014, Science Translational Medicine.

[31]  A. Rizzo,et al.  Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. , 2014, Rheumatology.

[32]  H. Yamanaka,et al.  IL-6, IL-8, and IL-10 Are Associated with Hyperferritinemia in Rapidly Progressive Interstitial Lung Disease with Polymyositis/Dermatomyositis , 2014, BioMed research international.

[33]  Q. Tang,et al.  Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma , 2013, Mediators of inflammation.

[34]  J. Gudjonsson,et al.  Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation , 2013, The Journal of Immunology.

[35]  V. Poli,et al.  IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? , 2012, Frontiers in bioscience.

[36]  L. Xia,et al.  Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis , 2011, Scandinavian journal of rheumatology.

[37]  P. Miossec,et al.  Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. , 2010, Arthritis and rheumatism.

[38]  C. Tato,et al.  Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.

[39]  B. Feldman,et al.  Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies , 2010, Arthritis care & research.

[40]  Toshio Hirano,et al.  Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.

[41]  M. Febbraio,et al.  Muscle as an endocrine organ: focus on muscle-derived interleukin-6. , 2008, Physiological reviews.

[42]  Toshio Hirano,et al.  IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. , 2007, International immunology.

[43]  P. Christadoss,et al.  Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. , 2006, Cytokine.

[44]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[45]  P. Miossec,et al.  Interleukin-17 increases the effects of IL-1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis , 2003, Journal of Neuroimmunology.

[46]  J. Steinke,et al.  2. Cytokines and chemokines. , 2003, The Journal of allergy and clinical immunology.